$15.2M Valsartan, Losartan and Irbesartan class action settlement

Aurobindo, Hetero and Vivimed agreed to class action settlements totaling more than $15.2 million to resolve claims that their blood pressure medications were contaminated with cancer-causing substances.

Aurobindo agreed to a $2 million class action settlement, Hetero a $11,365,489.80 settlement and Vivimed a $1,899,000 settlement to resolve claims that their irbesartan, valsartan and losartan blood pressure medications were contaminated with cancer-causing substances.

All three class action settlements are part of the same larger federal litigation — In re: Valsartan, Losartan and Irbesartan Products Liability Litigation — currently pending in the United States District Court for the District of New Jersey.

The Aurobindo settlement benefits consumers who paid for irbesartan medications manufactured with Aurobindo irbesartan active pharmaceutical ingredient (API) since Jan. 1, 2016. The Hetero settlement benefits consumers who paid for valsartan medications manufactured using Hetero Process III API sold between May 1, 2018, and July 31, 2018. The Vivimed settlement benefits consumers who paid for Vivimed losartan finished drug formulations sold under specific impacted National Drug Codes (NDCs).

The class action lawsuit claimed that medications from pharmaceutical manufacturers Aurobindo (irbesartan), Hetero (valsartan) and Vivimed (losartan) were contaminated with nitrosamine impurities — NDEA, NDMA and NMBA, respectively — all alleged to be human carcinogens.

The plaintiffs in the cases say that each manufacturer knew or should have known that its medication was contaminated with these impurities. However, the companies allegedly failed to warn consumers and retailers about the contamination. As a result of each defendant’s alleged failure to warn, consumers were forced to overpay for the contaminated medications.

Aurobindo, Hetero and Vivimed have each denied any wrongdoing but agreed to resolve these allegations with their respective settlements.

Under the terms of the Aurobindo class action settlement, class members can receive a cash payment based on the amount they paid for irbesartan medications. Class members who paid out of pocket for irbesartan medications can receive a reimbursement of up to $100. Class members who have documentation of their purchases can receive a larger reimbursement of up to $200.

Under the terms of the Hetero settlement, consumers can generally receive up to $40 for each 30-day supply purchased, with a maximum total payment of $120. However, consumers who can sufficiently document purchases in excess of $40 for a 30-day supply may receive a higher payment without regard to the standard caps.

Payment amounts for individual Vivimed class members have not yet been specified, as the allocation method is to be determined by class counsel and reviewed by the court prior to the final approval hearing.

For the Aurobindo and Hetero class action settlements, the deadline for exclusion, objection and claim submission is June 2, 2026, and the final approval hearing is scheduled for June 30, 2026. Deadlines for the Vivimed settlement have not yet been set by the court.

Who’s Eligible

The Aurobindo settlement benefits consumers who paid for irbesartan medications manufactured with Aurobindo irbesartan active pharmaceutical ingredients since Jan. 1, 2016. The Hetero settlement benefits consumers who paid for valsartan medications manufactured using Hetero Process III API sold between May 1, 2018 and July 31, 2018. The Vivimed settlement benefits consumers who paid for Vivimed losartan finished drug formulations sold under specific impacted National Drug Codes.

Potential Award

Aurobindo class members can receive a cash payment of up to $100 based on the amount they paid for irbesartan medications. Class members who have documentation of their purchases can receive a larger reimbursement of up to $200.

Hetero class members can receive up to $40 for each 30-day supply purchased, with a maximum total payment of $120. Members with proof of purchase in excess of $40 for a 30-day supply may receive a higher payment without regard to the standard caps.

Vivimed class members have not yet been specified, as the allocation method is to be determined by Class Counsel and reviewed by the court prior to the final approval hearing.

Proof of Purchase

Documentation such as pharmacy receipts

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

06/02/2026

Case Name

In re: Valsartan, Losartan and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK, in the United States District Court for the District of New Jersey

Final Hearing

06/30/2026

Settlement Website

SartanMedicationSettlement.com

Claims Administrator

Sartan Medication Settlement Administrator
P.O. Box 3376
Baton Rouge, LA 70821
[email protected]
866-875-9644

Class Counsel

John R. Davis
SLACK DAVIS SANGER LLP

Ruben Honik
HONIK LAW

Conlee S. Whiteley
KANNER & WHITELEY LLC

Defense Counsel

Aurobindo:
John P. Lavelle
MORGAN, LEWIS & BOCKIUS LLP

Hetero:
Eric Abraham
HILL WALLACK LLP

Terry M. Henry
BLANK ROME LLP

Andrew F. Albero
LEWIS BRISBOIS

Vivimed:Douglas Tween
John Eichlin
LINKLATERS LLP